Skip to content
← Catalog

Best Pract Res Clin Rheumatol 2026 · CAR-T 'Living drugs' in SLE · Khalili/Askanase

"Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative therapeutic option for patients with severe, refractory autoimmune conditions. Since 2022, several authors have published their experience using CAR T-cell therapy for patients with systemic lupus er…

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_verify_wave_3_2026-05-16
evidence_grade
A
category
car_t_sle_autoimmune
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"review of SLE CAR-T clinical experience · early-stage data · not intended to guide individual patient treatment choices"
journal
Best Practice & Research Clinical Rheumatology
year
2026
authors
Leila Khalili,Anca Askanase
abstract_snippet
"Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative therapeutic option for patients with severe, refractory autoimmune conditions. Since 2022, several authors have published their experience using CAR T-cell therapy for patients with systemic lupus
pmid
41956929
doi
10.1016/j.berh.2026.102141
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.